Effects of Dalfampridine on Cognition in Multiple Sclerosis
Status:
Completed
Trial end date:
2016-02-01
Target enrollment:
Participant gender:
Summary
Cognitive impairment is common in multiple sclerosis (MS) and has devastating impact on
functional activities. There is great demand for medications that will enhance cognitive
capacity in MS patients. To date, there is no evidence for improvement in cognition following
treatment with aminopyridines, but the few studies on the topic included neuropsychological
(NP) tests as secondary or tertiary outcomes, and were methodologically flawed. Dalfampridine
may enhance cognition by direct pharmacological mechanisms, and should have effects on motor
outcomes as in prior studies. By combining cognition and motor outcomes in the proposed
study, the investigators will evaluate if the same patients with positive effects show
beneficial responses on motor outcomes including physical activity and if such motor outcomes
mediate and/or moderate cognitive improvements with dalfampridine